drugset / Trial / NCT02183103

Influence of a High Fat Breakfast in the Pharmacokinetics of UH-AC62MU in Healthy Subjects

NCT02183103

Phase 1 Completed 8 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Influence of a high fat breakfast in the pharmacokinetic profile of the 7.5 mg meloxicam rapid releases tablet

Timeline

Start
1999-04
Primary completion
1999-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 7.5 mg Oral

Indications

No indication recorded.